Results 71 to 80 of about 5,788 (178)

Assessment of auditory function in hepatitis “C” patients managed by combination of sofosbuvir and daclatsavir

The Egyptian Journal of Otolaryngology, 2022
Background To evaluate the effect of daclatasvir and sofosbuvir on auditory function in hepatitis C patients. Thirty hepatitis C virus (HCV) patients were included in this study with age ranged from 22 to 55 years.
El-Zahraa M. Meghezel, Mohammed A. Abd Al-Ghaffar, Asmaa Naser Mohammad, Samar M. Mahmoud, Usama M. Abdelaal, Salwa Mourad   +5 more
doaj   +1 more source

Comparison of Interferon‐Based and Interferon‐Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus‐Sustained Virological Response: A Multicenter Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Shinji Itoh, Norifumi Iseda, Tomoharu Yoshizumi, Takao Ide, Hirokazu Noshiro, Hisamune Sakai, Toru Hisaka, Masao Nakashima, Hiroaki Nagano, Hirohisa Okabe, Hiromitsu Hayashi, Atsushi Miyoshi, Kenji Kitahara, Yuko Takami, Atsushi Nanashima, Tamotsu Kuroki, Yuichi Endo, Kohji Okamoto, Masatoshi Kajiwara, Masahiko Sakoda, Toru Beppu, Mitsuhisa Takatsuki, Susumu Eguchi   +22 more
wiley   +1 more source

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Aadil Nabi Mir, Mohammad Ashraf Bhat, Irshad Ahmad Parray, Manzoor Ahmad Parry   +3 more
core   +1 more source

Possible acute rejection associated with the use of the new antihepatitis C virus medications

Avicenna Journal of Medicine, 2019
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant.
Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes   +4 more
doaj   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Daclatasvir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Daclatasvir sensitivity profile and validation.

, 2014
(A) A heat map shows the fitness landscape shift under Daclatasvir treatment (20 pM), which is calculated as the ratio of relative fitness scores (Wdrug/Wcontrol). The mutants that are lethal without drug are shown in grey. The secondary structure of DIA
Virginia Chu (549943), Shawna Truong (549944), James O. Lloyd-Smith (24136), Ren Sun (82856), Laith Q. Al-Mawsawi (307260), Nicholas C. Wu (549942), Claude Loverdo (434144), C. Anders Olson (549941), Sheng-Yao Su (368663), Roland Remenyi (270101), Chung-Yen Lin (10205), Zugen Chen (76247), Ruian Ke (102243), Ting-Ting Wu (1693231), Hangfei Qi (549940), Weidong Zhong (120728), Yushen Du (549945), Shu-Hua Chen (549946)   +17 more
core   +1 more source

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Pakistan Armed Forces Medical Journal, 2020
Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar   +5 more
doaj  

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source